FMP
Mar 14, 2023 11:06 PM - Davit Kirakosyan(Last modified: Dec 19, 2023 5:49 PM)
Seagen Inc. (Nasdaq:SGEN) shares gained more than 14% on Monday after the company announced it had entered into a definitive merger agreement with Pfizer Inc. (NYSE:PFE), under which Pfizer will acquire Seagen for $229 in cash per Seagen share for a total enterprise value of $43 billion.
According to the analysts at Oppenheimer, the deal a positive for both sides of the proposed transaction and they are encouraged by favorable M&A dynamics which they suspect could lead to additional biopharma deals including (1) drug development synergies enhanced by IRA nuances rewarding full development in parallel upfront as opposed to the staged label expansion in series that previously dominated oncology clinical programs, (2) access to Pfizer's massive medicinal chemistry and machine learning platform to facilitate novel ADC discovery beyond what Seagen could achieve independently, and (3) fully integrated global infrastructure enabling Pfizer to commercialize Seagen’s R&D portfolio no longer required to share across external geographical partners.
Oct 31, 2023 8:03 AM - Parth Sanghvi
Free cash flow to the firm (FCFF) and free cash flow to equity (FCFE) are two of the most important metrics used in financial modeling. Both metrics measure the amount of cash that is available to a company's shareholders and creditors, but there is a key difference between the two. FCFF measures...
Nov 25, 2023 6:39 AM - Parth Sanghvi
Choosing the Right Valuation Method: DCF vs. Comparable Companies Analysis Introduction: Valuation methods play a pivotal role in determining the fair value of a company, aiding investors in making informed investment decisions. Two commonly used methods, DCF Valuation and Comparable Companies A...
Dec 23, 2023 2:19 AM - Parth Sanghvi
Introduction: Discounted Cash Flow (DCF) analysis stands as a cornerstone in valuing investments, yet its efficacy is contingent upon various assumptions and methodologies. While a powerful tool, DCF analysis comes with inherent limitations and challenges that investors must acknowledge to make i...